Ubiquitin–proteasome system (UPS) as a target for anticancer treatment
- 주제(키워드) Cancer , Deubiquitinating enzymes (DUBs) , E3 ligase , Proteasome , Small molecule inhibitors , Ubiquitin–proteasome system (UPS)
- 등재 SCIE, SCOPUS, KCI등재
- OA유형 Green Published, Bronze
- 발행기관 Pharmaceutical Society of Korea
- 발행년도 2020
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000175075
- 본문언어 영어
- Published As http://dx.doi.org/10.1007/s12272-020-01281-8
- PubMed https://pubmed.ncbi.nlm.nih.gov/33165832
- 저작권 이화여자대학교 논문은 저작권에 의해 보호받습니다.
초록/요약
The ubiquitin–proteasome system (UPS) plays an important role in the cellular processes for protein quality control and homeostasis. Dysregulation of the UPS has been implicated in numerous diseases, including cancer. Indeed, components of UPS are frequently mutated or abnormally expressed in various cancers. Since Bortezomib, a proteasome inhibitor, received FDA approval for the treatment of multiple myeloma and mantle cell lymphoma, increasing numbers of researchers have been seeking drugs targeting the UPS as a cancer therapeutic strategy. Here, we introduce the essential component of UPS, including ubiquitinating enzymes, deubiquitinating enzymes and 26S proteasome, and we summarize their targets and mechanisms that are crucial for tumorigenesis. In addition, we briefly discuss some UPS inhibitors, which are currently in clinical trials as cancer therapeutics. © 2020, The Pharmaceutical Society of Korea.
more